摘要 |
The disclosure relates to an agent or agents that inhibit the activity of both, Tumour Necrosis Factor Apoptosis-Inducing Ligand [TRAIL] and osteoprotegerin (OPG) and their use in the treatment of pulmonary hypertension and including agents that bind OPG ligands/receptors |